Showing 5091-5100 of 7761 results for "".
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- Foamix Receives USPTO Patents for Topical Tetracyclineshttps://practicaldermatology.com/news/20141113-foamix_receives_uspto_patents_for_topical_tetracyclines/2459066/Foamix Pharmaceuticals Ltd., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that the United States Patent and Trademark Office ("USPTO") has recently issued to it two additi
- Oculus Innovative Sciences Commercializes Microcyn-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europehttps://practicaldermatology.com/news/20141113-oculus_innovative_sciences_commercializes_microcyn-based____solution_and_hydrogel_for_treatment_of_mild-to-moderate_acne_in_europe/2459068/Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in 37 countries, today announced the European commercialization of Microcyn(R)-based GramaDerm(TM) Solution a
- Skin Cancer Foundation: Dermatologists and Beauty Professionals Team Up to Spot Skin Cancershttps://practicaldermatology.com/news/20141113-skin_cancer_foundation_dermatologists_and_beauty_professionals_team_up_to_spot_skin_cancers/2459069/The Skin Cancer Foundation is encouraging dermatologists and beauty professionals to work together through an education program called Heads Up! The skin cancer awareness program provides beauty professionals, including hair stylists and aestheticians, with tips on what to look for, and how to speak
- Brodalumab Outperforms Ustekinumab in Head-to-Head Trialhttps://practicaldermatology.com/news/20141112-brodalumab_outperforms_ustekinumab_in_head-to-head_trial/2459070/New findings from the Phase III AMAGINE-3 trial suggest that the investigational IL-17 inhibitor brodalumab (Amgen/AstraZeneca) may be superior to ustekinumab in treating patients with moderate to severe psoriasis. In the study, investigators evaluated more than 1,800 patients who were randomized to
- Promius Pharma Launches Promiseb Topical Cream 60 Gram Optionhttps://practicaldermatology.com/news/20141105-promius_pharma_launches_promiseb_topical_cream_60_gram_option/2459073/Promius Pharma LLC launched Promiseb Topical Cream in a new 60 gram box. This well-regarded non-steroidal cream for the treatment of seborrheic
- Women's Rogaine 5% Minoxidil Topical Aerosol Receives FDA Approvalhttps://practicaldermatology.com/news/20141104-womens_rogaine_5_minoxidil_topical_aerosol_receives_fda_approval/2459075/The official launch to market of Women's Rogaine 5% Minoxidil Topical Aerosol, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair. Women's Rogai
- Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removalhttps://practicaldermatology.com/news/20141103-syneron_candela_announces_fda_clearance_of_picoway_picosecond_laser_for_tattoo_removal/2459076/The FDA granted 510(K) clearance to Syneron Candela's PicoWay picosecond device for tattoo removal. PicoWay is a dual wavelength device, with 1064nm and 532nm wavelengths, which utilizes the proprietary PicoWay Technology to generate picosecond pulses for the removal of tattoos. The FDA clearanc
- Harvard Business Review Names Allergan's David E. I. Pyott a Top CEOhttps://practicaldermatology.com/news/20141015-harvard_business_review_names_allergans_david_e_i_pyott_a_top_ceo/2459084/David E.I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan, Inc., has been ranked the 4th best-performing CEO in the world by the Harvard Business Review (HBR). Mr. Pyott was selected for this honor out of a total o
- New Data for Topical Nitric Oxide Nanoparticles: Evidence in Animal Model of EDhttps://practicaldermatology.com/news/20141014-new_data_for_topical_nitrous_oxide_nanoparticles_evidence_in_animal_model_of_ed/2459086/Topically applied nitric oxide-releasing nanoparticles (NO-NPs) induced spontaneous erections and increased basal ICP in an animal model of radical prostatectomy. According to findings published in The Journal o